Agenda
*All times are in PDT
Aug
Sat 26
Meeting objectives & introduction
Naval Daver & Andrew Wei
Session 1: New research perspectives in AML
Chairs: Ravi Majeti & TBC
- Immunological perspectives of long-term survivors: Paresh Vyas
- Clonal Evolution in AML: Ravi Majeti
- Predictors of transformation in CHIP and CCUS and ways to optimize prediction: Koichi Takahashi
- Potential for early intervention in CHIP and CCUS: Uma Borate
- Familial Leukemia predispositions: Understanding, identifying, and monitoring: Courtney DiNardo
- Harnessing epigenetic information in AML to identify novel potential therapeutic approaches: Maria Figueroa
Panel discussion
Break
Session 2: Controversies in AML
Chairs: Gail Roboz & Naval Daver
- Improving intensive chemotherapy approaches in frontline AML: Tapan Kadia
- Which patients should have allogeneic transplants in 2023?: Charles Craddock
- Optimal transplant conditioning regimen in AML: Betul Oran
- Intensive chemo or HMA Ven intermediate for younger AML patients?: Eunice Wang
Panel discussion
- Optimizing therapy in secondary AML and optimal use of CPX-351: Harry Erba
- Clinical approaches for IDH-mutated AML: TBC
- Current approaches for relapsed FLT3-mutant AML: Jessica Altman
Panel discussion
Session 3: New frontiers in MRD for AML clinical practice
Chairs: Richard Stone & Marina Konopleva
- Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
- Value of MRD assessment in non-intensive regimens in AML: Farhad Ravandi
- MRD as a clinical endpoint in clinical trials: Roland Walter
- Applying MRD techniques in FLT3 mutated AML – are we able to use MRD as an endpoint in FLT3 AML?: Alexander Perl
- MRD-directed interventions: Andrew Wei
Panel discussion
Lunch
Special Session: Regulatory endpoints in AML
Chairs: Courtney DiNardo & Mark Levis
- The FDA’s perspective on regulatory endpoints in AML: Joseph Wynne
- A clinical investigator’s perspective on endpoints and drug development in AML: Naval Daver
Panel discussion with Joseph Wynne, Naval Daver
Session 4: BPDCN & MDS/MPN + CMML
Chairs: Naveen Pemmaraju & TBC
- Updates in diagnosis, pathogenesis and future directions in BPDCN: Naveen Pemmaraju
- Current and new directions for accelerated/BP/transformed MPN: Anand Patel
- VEXAS: a new entity: Emma Groarke
- Future targets and drug development in CMML: Mrinal Patnaik
- Bench to bedside in MPNs: CALR and targeting CALR: Jyoti Nangalia
- Novel targeted Agents in MPNs: TBC
Panel discussion
Break
Session 5: Novel targets, combinations and treatments in AML
Chairs: Andrew Wei and Eunice Wang
Keynote talk
History of development and future directions for FLT3 inhibitors in AML: Mark Levis
New AML therapies and limitations
Chairs: Andrew Wei & Eunice Wang
- Optimizing doublet and triplet combinations in AML: improving efficacy while maintaining safety: Naval Daver
- Emerging novel antibody-drug conjugates: TBC
- Uproleselan in frontline and R/R AML: Geoffrey Uy
- TP53 treatment strategies in AML: Thomas Cluzeau
Panel discussion
- Menin inhibitors in AML: Ghayas Issa
- Mechanisms of resistance and combination approaches with Menin inhibitors in AML: Eytan Stein
- Targeting resistance to venetoclax-based therapies: Marina Konopleva
- Resistance to FLT3 inhibitors: Catherine Smith
Panel discussion
Day 1 summary
Aug
Sun 27
Meeting objectives & introduction
Naval Daver & Andrew Wei
Session 5, Part 2: Novel targets, combinations, and treatments in AML
What do we know about drug resistance?
Chairs: Charles Craddock and Courtney DiNardo
- Genomic landscape and prognostic implications of TP53 mutations in AML: Sanam Longhavi
- Magrolimab combinations: Naval Daver
- TP53 reactivators: David Sallman
- Novel pro-survival combinations: Andrew Wei
- When and who to transplant?: Betul Oram
Session 6: New therapies in the AML transplant setting
Chairs: Charles Craddock & TBC
- Vedolizumab for for prophylaxis and treatment of acute GVHD post alloSCT: Yngvar Fløisand
- Improving outcomes post-BMT with Iomab-B: TBC
- Cell-therapy for Epstein-Barr+ post-transplant lymphoproliferative disease: TBC
- Treating transplant-related TMA (HSCT-TMA) in AML patients: TBC
- Updates in use of post-transplant cyclophosphamide: Nelli Bejanyan
Panel discussion
Break
Session 7: Immunotherapeutics in AML
Chairs: David Sallman & John DiPersio
- Immunotherapy TME & Beyond: John DiPersio
- What Antigen should we Target in R/R AML? TBC
- Novel T-Cell Approaches for R/R AML, excluding CAR-T: Nelli Bejanyan
- NK cells & CAR NK cells: Naval Daver
- Outcomes in early-phase CAR-T clinical trials for R/R AML and MDS: David Sallman
Panel discussion
Conclusions & Meeting Close